Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	185	127	206	148	173.62	58.14
Short-Term Investments	810	632	803	351	555.23	130.33
Cash & Cash Equivalents	995	759	1,009	499	728.85	188.47
Cash Growth	4.30%	-24.78%	102.20%	-31.54%	286.71%	-26.59%
Receivables	35	38	39	745	1.05	0.13
Other Current Assets	34	34	19	18	5.92	4.1
Total Current Assets	1,064	831	1,067	1,262	735.82	192.71
Property, Plant & Equipment	51	51	35	32	23.59	9.33
Long-Term Investments	100	107	129	182	6.44	0
Other Long-Term Assets	78	106	114	116	6.45	1.08
Total Long-Term Assets	229	264	278	330	36.48	10.41
Total Assets	1,293	1,095	1,345	1,592	772.29	203.11
Accounts Payable	16	17	20	10	15.68	4.7
Deferred Revenue	366	398	452	564	207.1	19.02
Other Current Liabilities	-178	-231	-279	-408	-101.12	-1.02
Total Current Liabilities	204	184	193	166	121.67	22.71
Long-Term Debt	0	0	0	0	15.24	0
Other Long-Term Liabilities	382	449	495	584	133.08	16.56
Total Long-Term Liabilities	382	449	495	584	148.32	16.56
Total Liabilities	586	633	688	750	269.99	39.27
Total Debt	0	0	0	0	15.24	0
Retained Earnings	-853	-849	-542	-275	-328.18	-205.33
Comprehensive Income	-1	0	-7	-1	0.04	0.06
Shareholders' Equity	707	462	657	842	502.3	163.84
Net Cash / Debt	995	759	1,009	499	713.61	188.47
Net Cash / Debt Growth	4.30%	-24.78%	102.20%	-30.07%	278.63%	-26.59%
Net Cash Per Share	11.54	10.26	14.01	6.74	13.02	4.30
Working Capital	860	647	874	1,096	614.15	170
Book Value Per Share	8.20	6.24	9.13	12.15	9.17	3.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).